For information on a site near you, call 1-800-244-7668 Option "2" — Long Beach, California

For information on a site near you, call 1-800-244-7668 Option "2" is a clinical research site located in Long Beach, California, United States.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

For information on a site near you, call 1-800-244-7668 Option "2" has participated in 1 clinical trials.

Therapeutic areas: Cystic Fibrosis.

Sponsors: Novartis.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Long Beach

Browse all research sites in California · View every site in Long Beach

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for For information on a site near you, call 1-800-244-7668 Option "2"?

For information on a site near you, call 1-800-244-7668 Option "2" has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has For information on a site near you, call 1-800-244-7668 Option "2" conducted?

For information on a site near you, call 1-800-244-7668 Option "2" has 1 clinical trials on record. Their work covers Cystic Fibrosis.

Is For information on a site near you, call 1-800-244-7668 Option "2" accredited by Crixeo Clinical Trials?

For information on a site near you, call 1-800-244-7668 Option "2" has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about For information on a site near you, call 1-800-244-7668 Option "2"?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.